7.17
price down icon1.78%   -0.13
after-market 시간 외 거래: 7.17
loading

Sage Therapeutics Inc 주식(SAGE)의 최신 뉴스

pulisher
May 04, 2025

Invesco Ltd. Purchases 4,629 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

May 04, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

What is HC Wainwright’s Forecast for SAGE Q1 Earnings? - Defense World

May 02, 2025
pulisher
May 01, 2025

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN

May 01, 2025
pulisher
May 01, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025
pulisher
Apr 30, 2025

Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Balance Sheet Breakdown: Sage Therapeutics Inc (SAGE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ... - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

SAGE Reports Q1 Revenue Below Estimates, Highlights ZURZUVAE Gro - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: S - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Sage Therapeutics Reports Strong Q1 2025 Performance - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Sage Therapeutics outlines Q1 2025 growth in ZURZUVAE prescriptions and pipeline progress - MSN

Apr 30, 2025
pulisher
Apr 30, 2025

Sage Therapeutics Q1 2025 Earnings: Revenue at $13.8M Misses Est - GuruFocus

Apr 30, 2025
pulisher
Apr 29, 2025

Sage Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SAGE) - Seeking Alpha

Apr 29, 2025
pulisher
Apr 29, 2025

Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast By Investing.com - Investing.com Nigeria

Apr 29, 2025
pulisher
Apr 29, 2025

Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Sage Therapeutics Announces First Quarter 2025 Financial Results - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq

Apr 29, 2025
pulisher
Apr 29, 2025

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

SAGE THERAPEUTICS Earnings Results: $SAGE Reports Quarterly Earnings - Nasdaq

Apr 29, 2025
pulisher
Apr 28, 2025

What to Expect from Sage Therapeutics's Earnings - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Get in on Sage Therapeutics Inc’s (SAGE) buy-in window today! - Sete News

Apr 28, 2025
pulisher
Apr 28, 2025

Sage Therapeutics Inc [SAGE] Insider Activity: An Update for Investors - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Sage Therapeutics’ (SAGE) “Hold” Rating Reiterated at Needham & Company LLC - Defense World

Apr 28, 2025
pulisher
Apr 25, 2025

Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts - Benzinga

Apr 25, 2025
pulisher
Apr 25, 2025

Geode Capital Management LLC Increases Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Apr 25, 2025
pulisher
Apr 24, 2025

Russell Investments Group Ltd. Lowers Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Apr 24, 2025
pulisher
Apr 22, 2025

Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - PR Newswire

Apr 22, 2025
pulisher
Apr 22, 2025

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Apr 22, 2025
pulisher
Apr 22, 2025

Sage Therapeutics (SAGE) Projected to Post Quarterly Earnings on Tuesday - Defense World

Apr 22, 2025
pulisher
Apr 22, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of “Hold” by Analysts - Defense World

Apr 22, 2025
pulisher
Apr 20, 2025

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 20, 2025
pulisher
Apr 20, 2025

Wedbush Research Analysts Raise Earnings Estimates for SAGE - American Banking and Market News

Apr 20, 2025
pulisher
Apr 19, 2025

Lobbying Update: $50,000 of SAGE THERAPEUTICS lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 19, 2025

Q1 EPS Estimates for Sage Therapeutics Increased by Wedbush - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Q1 Earnings Forecast for SAGE Issued By Wedbush - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - markets.businessinsider.com

Apr 17, 2025
pulisher
Apr 15, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - markets.businessinsider.com

Apr 15, 2025
pulisher
Apr 15, 2025

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 | SAGE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Corebridge Financial Inc. Sells 2,050 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 13, 2025

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Apr 13, 2025
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
자본화:     |  볼륨(24시간):